Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Cancer Lett. 2017 Jul 1;397:94-102. doi: 10.1016/j.canlet.2017.02.020. Epub 2017 Feb 27.
Pancreatic cancer, which is often asymptomatic, is currently one of the most common causes of cancer-related death. This phenomenon is most likely due to a lack of early diagnosis, a high metastasis rate and a disappointing chemotherapy outcome. Thus, improving treatment outcomes by overcoming chemotherapy resistance may be a useful strategy in pancreatic cancer. Various underlying mechanisms involved in the chemoresistance of pancreatic cancer have been investigated. Notably, non-coding RNAs (ncRNAs), especially microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), play a pivotal role in regulating sensitivity to chemotherapy in pancreatic cancer. In this review, we highlight recent evidence regarding the role of miRNAs and lncRNAs in the chemoresistance of pancreatic cancer, including their expression levels, targets, biological functions and the regulation of chemoresistance, and discuss the potential clinical application of miRNAs and lncRNAs in the treatment of pancreatic cancer.
胰腺癌通常无症状，目前是癌症相关死亡的最常见原因之一。这种现象很可能是由于缺乏早期诊断、高转移率和令人失望的化疗结果所致。因此，通过克服化疗耐药性来提高治疗效果可能是胰腺癌的一种有效策略。已经研究了涉及胰腺癌化疗耐药性的各种潜在机制。值得注意的是，非编码 RNA（ncRNA），特别是 microRNAs（miRNAs）和长非编码 RNA（lncRNAs），在调节胰腺癌对化疗的敏感性方面发挥着关键作用。在这篇综述中，我们强调了最近关于 miRNAs 和 lncRNAs 在胰腺癌化疗耐药性中的作用的证据，包括它们的表达水平、靶标、生物学功能以及对化疗耐药性的调节，并讨论了 miRNAs 和 lncRNAs 在胰腺癌治疗中的潜在临床应用。
